High expression of cytoskeletal protein drebrin in TEL/AML1pos B-cell precursor acute lymphoblastic leukemia identified by a novel monoclonal antibody
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21497902
DOI
10.1016/j.leukres.2011.03.028
PII: S0145-2126(11)00164-0
Knihovny.cz E-resources
- MeSH
- Acute Disease MeSH
- Oncogene Proteins, Fusion MeSH
- Humans MeSH
- RNA, Messenger genetics MeSH
- Antibodies, Monoclonal immunology MeSH
- Mice MeSH
- Neuropeptides immunology metabolism MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics immunology metabolism MeSH
- Prognosis MeSH
- Core Binding Factor Alpha 2 Subunit MeSH
- Flow Cytometry MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- drebrins MeSH Browser
- Oncogene Proteins, Fusion MeSH
- RNA, Messenger MeSH
- Antibodies, Monoclonal MeSH
- Neuropeptides MeSH
- Core Binding Factor Alpha 2 Subunit MeSH
- TEL-AML1 fusion protein MeSH Browser
The expression of drebrin, a cytoskeletal protein newly estimated by expression profiling to correlate with the genotype and prognosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), was examined by independent methods. After demonstrating its higher expression in TEL/AML1(pos) BCP-ALL by quantitative reverse transcriptase polymerase chain reaction, we developed an anti-drebrin monoclonal antibody (mAb). In a cohort of 86 children with BCP-ALL, we found increased expression of drebrin in TEL/AML1(pos) ALL. In conclusion, relationship of drebrin expression and prognosis or genotype can now be assessed using flow cytometry.
References provided by Crossref.org
High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells
